Skip to main content

Neurochemistry Changes Associated with Mutations in Familial Parkinson's Disease

Buy Article:

$55.00 plus tax (Refund Policy)

Parkinson's disease (PD), a common neurodegenerative disease, is characterized by the progressive loss of dopamine neurons and the accumulation of Lewy bodies and neurites. The exact role of genetic and environmental factors in the pathogenesis of PD has frequently been debated. The association of MPTP (methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine) and toxins (such as rotenone) with parkinsonism highlights the potential etiologic role of environmental toxins in disease causation. The recent discoveries of monogenic (such as α-synuclein, Parkin, UCHL1, PINK1, DJ-1, LRRK2) forms of PD have provided considerable insights into its pathophysiology. Parkin, an ubiquitin protein ligase assists in the degradation of toxic substrates via the ubiquitin proteasome system. It can also mediate a nondegradative form of ubiquitination. PINK1 and LRRK2 are possibly involved in the phosphorylation of substrates important for various cellular functions. Some toxins could interact with α-synuclein, an endogenous protein that is implicated in pathology of PD. Increasing in vitro and in vivo studies suggest that deficits in mitochondrial function, oxidative and nitrosative stress, the accumulation of aberrant or misfolded proteins, and ubiquitin-proteasome system dysfunction underpin the pathogenesis of sporadic and familial forms of PD. Elucidation of the functions of the proteins encoded by the diseasecausing genes will provide an opportunity for identification of specific pathways that could be targeted in neurotherapeutics.





No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: AIF; ATM; ATP13A2; Akt1; Akt2; Bcl-2; Cytochrome C; DA; DJ 1; Depolymerization; Dictyostelium discoidum; Dopamine; Drosophila; E2F; ERM; FeCl2; G2385R; GTPase; Granzyme M; HSPs; HtrA2; LRRK2; Lewy bodies; MPTP; Microglial; Mutations; NF-B; Neurochemistry; OHDA; PI3K; PINK-1; PINK1; PTM; Parkin; Parkinson's disease (PD); RNAi; ROS; RanBP2; SIAH-1; SNpc; Synuclein; TRAP1; UCH-L1 (PARK5); UPS; XIAP; apoptosis; exocytosis; homeostasis; leucine-rich repeat kinase 2; lysosomal; mitochondrial dysfunction; neurites; neurotoxicity; pathophysiology; phosphorylation; protein; protein aggregation; rotenone; synucleinases; toxicity; toxins; ubiquitin

Document Type: Research Article

Publication date: 2010-12-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more